| Literature DB >> 29681675 |
Anna Gatti1,2, Abraha Habtemariam2, Isolda Romero-Canelón2,3, Ji-Inn Song2, Bindy Heer2, Guy J Clarkson2, Dominga Rogolino1, Peter J Sadler2, Mauro Carcelli1.
Abstract
We report the synthesis, characterization, and antiproliferative activity of organo-Entities:
Year: 2018 PMID: 29681675 PMCID: PMC5908187 DOI: 10.1021/acs.organomet.7b00875
Source DB: PubMed Journal: Organometallics ISSN: 0276-7333 Impact factor: 3.876
Figure 1Schematic representation of ligands L1 and L2 and corresponding osmium(II) and ruthenium(II) complexes 1–4.
Figure 2X-ray crystal structures of complexes 1–4 with thermal ellipsoids drawn at 50% probability. Hydrogens are drawn as fixed-size spheres of 0.11 Å radius and solvent molecules have been omitted for clarity. The edge-to-face stacking between one of the hydrogens of the p-cymene ring and an aromatic ring of the thiosemicarbazone ligands is indicated.
Selected Bond Lengths (Å) and Angles (deg) for Complexes 1–4
| bond distance (Å) | bond angle (deg) | |||
|---|---|---|---|---|
| Os1–Cl1 | 2.4113(12) | S1–Os1–Cl1 | 86.52(4) | |
| Os1–S1 | 2.3551(13) | N4–Os1–Cl1 | 81.63(10) | |
| Os1–N4 | 2.118(4) | N4–Os1–S1 | 81.63(11) | |
| S1–C2 | 1.695(5) | |||
| H14–CE1 | 2.563 | |||
| Os1–Cl1 | 2.4030(5) | S8–Os1–Cl1 | 87.81(2) | |
| Os1–S8 | 2.3527(5) | N4–Os1–Cl1 | 83.44(5) | |
| Os1–N10 | 2.1227(17) | N10–Os1–S8 | 81.79(5) | |
| S8–C8 | 1.693(2) | |||
| H21–CE1 | 2.500 | |||
| Ru1–Cl1 | 2.4046(11) | S1–Ru1–Cl1 | 86.90(4) | |
| Ru1–S1 | 2.3501(10) | N4–Ru1–Cl1 | 83.06(9) | |
| Ru1–N4 | 2.125(3) | N4–Ru1–S1 | 81.95(10) | |
| S1–C2 | 1.695(4) | |||
| H14–CE1 | 2.548 | |||
| Ru1–Cl1 | 2.3993(3) | S8–Ru1–Cl1 | 88.338(11) | |
| Ru1–S8 | 2.3508(3) | N10–Ru1–Cl1 | 84.77(3) | |
| Ru1–N10 | 2.1256(9) | N10–Ru1–S8 | 81.94(3) | |
| S8–C8 | 1.6923(12) | |||
| H21–CE1 | 2.486 |
Figure 3Aromatic region of the time-dependent 1H NMR spectrum of 1 in MeOD-d4 at T = 298 K followed over 30 days. E and Z isomers are labeled as a and b sets, respectively. The percentage of the Z isomer (b set) increases with time.
Figure 4(A) E/Z interconversion for L1 and L2. (B) Chemical structures of the E and Z isomers of ligand L1 in the complex 1; the interaction between the iminic proton and one proton of the p-cymene is depicted by circles.
Scheme 1Proposed Mechanism for the E/Z Interconversion Process of the Coordinated Ligand L1 for Metal Complexes 1 and 3 in Methanol
Figure 5Aromatic region of the 1H NMR spectrum of 2 recorded in acetone-d6 at 298 K and followed over 7 days. Red circles indicate proton resonances related to the species with a coordinated solvent molecule.
Figure 6Comparison of the aromatic region of the 1H NMR of complex 1 (upper spectrum) and that of the corresponding free ligand L1 (lower spectrum) in DMSO-d6 at t = 0 and 298 K.
IC50 Values (μM) for L1 and L2 and Related Metal Complexes 1–4 towards Human Ovarian (A2780), Cisplatin-Resistant Ovarian (A2780Cis), Lung (A549), Colon (HCT116), and Prostate (PC3) Cancer Cell Linesa
| cell
lines IC50 (μM) | resistance factors | |||||
|---|---|---|---|---|---|---|
| compound | A2780 | A2780Cis | A549 | HCT116 | PC3 | A2780Cis/A2780 |
| 0.85 ± 0.03 | 0.12 ± 0.02 | 42 ± 2 | 30.6 ± 0.5 | 6.1 ± 0.1 | 0.14 | |
| 0.27 ± 0.02 | 1.23 ± 0.08 | 23 ± 1 | 33 ± 5 | 4.6 ± 0.2 | 4.55 | |
| 1.60 ± 0.02 | 6.6 ± 0.9 | 2.4 ± 0.2 | 24 ± 2 | 21 ± 1 | 4.12 | |
| 0.75 ± 0.08 | 7.2 ± 0.1 | 17 ± 1 | 2.7 ± 0.2 | 1.60 ± 0.08 | 9.60 | |
| 4.2 ± 0.3 | 5.6 ± 0.8 | 10.5 ± 0.3 | 19 ± 1 | 1.33 | ||
| 0.36 ± 0.03 | 1.25 ± 0.06 | 1.64 ± 0.08 | 1.38 ± 0.04 | 3.47 | ||
| CDDP | 1.2 ± 0.2 | 13.5 ± 0.3 | 3.1 ± 0.2 | 5.2 ± 0.1 | 9.8 ± 0.4 | 11.25 |
Clinical drug cisplatin (CDDP) is used as positive control.